Press Releases March 30, 2026 11:30 AM

FitLife Brands Announces Fourth Quarter Earnings Call

FitLife Brands Schedules Q4 2025 Earnings Release and Investor Call

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
FTLF

FitLife Brands announced it will release its fourth quarter fiscal 2025 financial results on March 31, 2026, followed by an investor conference call on April 1, 2026. The company specializes in nutritional supplements and wellness products and distributes over 500 SKUs online and in retail.

FitLife Brands Announces Fourth Quarter Earnings Call
FTLF
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • FitLife Brands to report Q4 fiscal 2025 earnings on March 31, 2026.
  • Investor call scheduled for April 1, 2026, to discuss financial results.
  • Company operates in nutritional supplements and wellness product sector with extensive product offerings.

OMAHA, NE, March 30, 2026 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. (“FitLife,” or the “Company”) (Nasdaq: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the fourth quarter of fiscal 2025 on Tuesday, March 31, 2026.

In addition, the Company announced that it will hold an investor conference call after market close on April 1, 2026 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 115536.  International participants can dial (973) 528-0163 and provide the same code.

About FitLife Brands
FitLife Brands is a developer and marketer of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers.  FitLife markets over 500 different products online and through various retail locations.  FitLife is headquartered in Omaha, Nebraska.  For more information, please visit our website at www.fitlifebrands.com.


Risks

  • Earnings results could fall short of investor expectations, affecting stock performance.
  • Market competition in the nutritional supplements sector may impact future growth.
  • Potential supply chain or regulatory challenges affecting product availability and compliance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026